Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.94 USD
+0.01 (0.36%)
Updated Aug 6, 2024 03:39 PM ET
After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LSTA 2.94 +0.01(0.36%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
Other News for LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics treatment of cholangiocarcinoma granted FDA orphan status
Lisata Therapeutics: A Strong Buy on Revolutionary Cancer Treatment Advancements
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD? Technology to Evaluate Efficacy of Pancreatic Cancer Therapy